Key result
The COMET trial enrolled 3029 patients with chronic heart failure to compare the effects of carvedilol versus metoprolol on morbidity and mortality, with follow-up until 1020 fatal events occur.
Why the study?
Does carvedilol compared to metoprolol tartrate improve morbidity and mortality in patients with chronic heart failure?
RCT (n=3,029)
Yes
Does carvedilol compared to metoprolol tartrate improve morbidity and mortality in patients with chronic heart failure?
This paper outlines the rationale and design of the COMET trial, which compares the effects of carvedilol versus metoprolol tartrate on morbidity and mortality in chronic heart failure.
Answers are grounded in this paper and cite their sources.
COMET RCT directly compares carvedilol versus metoprolol in chronic HF; extends prior beta-blocker evidence via head-to-head design.
In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morbidity in patients with chronic heart failure. Carvedilol is an adrenoceptor antagonist, which inhibits beta(1)-, beta(2)-, and alpha(1)-adrenergic receptors. Carvedilol has additional metabolic and antioxidant properties. Metoprolol is a selective antagonist of beta(1)-adrenergic receptors. The carvedilol or metoprolol European trial (COMET) is the first study to investigate whether beta-blocking agents with differing pharmacological profiles exert different effects on morbidity and mortality in patients with chronic heart failure. 3029 patients from 15 different European countries were enrolled into COMET and will be followed until 1020 fatal events have been observed, unless the data and safety monitoring committee (DSMC) recommends early termination. The target dose for carvedilol is 25 mg bid and for metoprolol tartrate 50 mg bid. This manuscript outlines the rationale, design and possible outcomes of COMET.
No takes yet. Share an insight, caveat, or question.
Poole‐Wilson et al. (2002) conducted an RCT in chronic heart failure (n=3,029). carvedilol vs. metoprolol tartrate 50 mg bid was evaluated on morbidity and mortality. The COMET trial enrolled 3029 patients with chronic heart failure to compare the effects of carvedilol versus metoprolol on morbidity and mortality, with follow-up until 1020 fatal events occur.
Synapse has enriched 10 related papers. Consider them for comparative context: